Annovis Bio is a clinical stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's disease in Down syndrome (AD-DS). Co.'s pipeline consists of: ANVS401, which is an orally administered drug being developed for chronic indications such as AD, PD and AD-DS by inhibiting the overproduction of neurotoxic proteins that kill nerve cells; ANVS405, which is focused on protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which increases cognitive capability in later stages of AD and dementia. The ANVS stock yearly return is shown above.
The yearly return on the ANVS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ANVS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|